|

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

RECRUITINGPhase 2Sponsored by Mayo Clinic
Actively Recruiting
PhasePhase 2
SponsorMayo Clinic
Started2026-03-01
Est. completion2026-12-31
Eligibility
Age18 Years – 50 Years
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06333652

Summary

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Eligibility

Age: 18 Years – 50 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Individuals with \< 34 0/7 weeks of gestation.
* Individuals with severe preeclampsia or HELLP features.

Exclusion Criteria:

* Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
* Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Conditions2

Liver DiseasePreeclampsia

Locations1 site

Mayo Clinic Minnesota
Rochester, Minnesota, 55905
Maria L. Gonzalez Suarez, MD,PhD5072844083gonzalezsuarez.maria@mayo.edu

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.